Live Breaking News & Updates on World Conference On Lung Cancer

Stay updated with breaking news from World conference on lung cancer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Patritumab Deruxtecan (HER3-DXd) in EGFR-Mutated NSCLC Following EGFR TKI and Platinum-Based Chemotherapy: HERTHENA-Lung01

Expert oncologist Helena Yu, MD, reviews data from HERTHENA-Lung01 following the IASLC 2023 World Conference on Lung Cancer and considers how patritumab deruxtecan will fit into clinical practice. ....

Helena Yu , Patritumab Deruxtecan , Lung Cancer , Non Small Cell Lung Cancer , Egfr Mutation , Egfr Lung Cancer , Egfr Tki , Herthena Lung01 , Her3 Dxd , Clinical Trials , Novel Therapy , World Conference On Lung Cancer , Wclc 2023 , 2023 Wclc , Efficacy Data , Safety Data , Her3 Membraneh Score , Her3 Expression , Cns Disease , Intracranial Disease , Adverse Events , Drug Adverse Event ,

AstraZeneca's Tagrisso cancer drug throws down the gauntlet for J&J rival

Adding chemotherapy cuts the risk of disease progression or death 38%, trial shows ....

United Kingdom , City Of , Pascal Soriot , Michel Demare , World Conference , 120923 Intbus Astrazeneca , J Amp , World Conference On Lung Cancer , Mail On Sunday , Usiness Live ,

Zongertinib Proves Clinically Active With Low Rate of EGFR-Mediated AEs in HER2-Mutant Solid Tumors

Treatment with at least 90 μg/kg of the novel DLLC-targeting T-cell–engager BI 764532 was well tolerated and led to tumor shrinkage in patients with small cell lung cancer and neuroendocrine carcinoma. ....

United States , Noboru Yamamoto , National Cancer Center Hospital , Department Of Experimental Therapeutics , Lung Cancer , Experimental Therapeutics , Middle East , World Conference On Lung Cancer , Her2 Mutant Solid Tumors , Zongertinib ,

Patritumab Deruxtecan Elicits Durable Responses in EGFR-Mutated NSCLC

Patritumab deruxtecan displayed clinically meaningful and durable efficacy in patients with advanced EGFR-mutated non–small cell lung cancer who experienced progression following treatment with an EGFR-directed TKI and platinum-based chemotherapy. ....

New York , United States , Memorial Sloan Kettering Cancer Center , Daiichi Sankyo , Helenaa Yu , Lung Cancer , Patritumab Deruxtecan , Non Small Cell Lung Cancer , Egfr Mutated Nsclc , Antibody Drug Conjugate , Her3 Dxd , Herthena Lung01 Trial , World Conference On Lung Cancer ,

Adagrasib Yields Durable Benefit for Patients With KRAS G12C–Mutant NSCLC

Adagrasib monotherapy provided durable efficacy for patients with KRAS G12C–mutated locally advanced or metastatic non–small cell lung cancer, according to 2-year follow-up data from the phase 1/2 KRYSTAL-1 trial.
....

United States , Shirishm Gadgeel , Adagrasib Krazati , Henry Ford Cancer Institute In Detroit , Lung Cancer , Henry Ford Cancer Institute , North America , International Association , Kras G12c , Non Small Cell Lung Cancer , Krystal 1 Trial , World Conference On Lung Cancer ,